Medexprim will:
EUCAIM brings together clinical data providers, researchers, research infrastructures and industry with mature solutions, to provide the means to build validated clinical decision-making systems supporting diagnosis, treatment, and predictive medicine to benefit citizens.
EUCAIM will:
“
Medexprim is thrilled to participate in a ground-breaking European federated infrastructure building on our involvement in 2 major AI4HI projects. The combined energy, expertise, and experience of this 76 parties-wide consortium will undoubtedly improve early detection and treatment options for cancer patients.
Clinical partners and external collaborators will populate the repository with multimodality imaging and related clinical data for historic and newly diagnosed cancer patients.
AI-powered pipelines will automate data de-identification, curation, annotation, integrity securing and image harmonization, enabling reproducibility of Radiomics with large image datasets.
Analytical data engine will interpret, extract and exploit the right information stored at the Repository.
Early in-silico validation of selected AI tools will be conducted in observational clinical studies coordinated by leading experts: San Donato (breast), Sapienza (colorectal), La Fe (prostate).
“
I am very proud and excited to take part to this ambitious EU project. It follows the Primage project in which we were already involved. It’s a big challenge, but it’s 100% in line with Medexprim’s core mission and expertise.
To integrate and validate a functional prototype of the PRIMAGE cloud-based platform offering predictive tools to assist management of Neuroblastoma and DIPG pediatric cancers, from diagnosis to prognosis, therapies choice and treatment follow-up, based on the use of novel imaging biomarkers, tumor growth models and advanced visualisation of predictions.